{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T13:16:50Z","timestamp":1763644610439,"version":"3.40.4"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,12]]},"DOI":"10.7759\/cureus.82134","type":"journal-article","created":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T21:15:17Z","timestamp":1744492517000},"source":"Crossref","is-referenced-by-count":1,"title":["A Curious Presentation of a Human Papillomavirus (HPV)-Driven Pelvic Squamous Cell Carcinoma of Unknown Primary: A Case Report"],"prefix":"10.7759","author":[{"given":"Georgia E","family":"Dau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra K","family":"Brennan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan J","family":"Teschan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jolyn S","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart S","family":"Winkler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2011.0117","article-title":"NCCN clinical practice guidelines occult primary","volume":"9","author":"Ettinger DS","year":"2011","unstructured":"Ettinger DS, Agulnik M, Cates JM, et al.. NCCN clinical practice guidelines occult primary. J Natl Compr Canc Netw. 2011, 9:1358-95. 10.6004\/jnccn.2011.0117","journal-title":"J Natl Compr Canc Netw"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg742","article-title":"Cancer of unknown primary: biological and clinical characteristics","volume":"14 Suppl 3","author":"Pavlidis N","year":"2003","unstructured":"Pavlidis N. Cancer of unknown primary: biological and clinical characteristics. Ann Oncol. 2003, 14 Suppl 3:iii11-8. 10.1093\/annonc\/mdg742","journal-title":"Ann Oncol"},{"key":"ref3","unstructured":"Cancers linked with HPV each year. (2024). Accessed. May 18, 2024: https:\/\/www.cdc.gov\/cancer\/hpv\/cases.html."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s13027-020-00310-x","article-title":"Multiplex HPV RNA in situ hybridization\/p16 immunohistochemistry: a novel approach to detect papillomavirus in HPV-related cancers. A novel multiplex ISH\/IHC assay to detect HPV","volume":"15","author":"Zito Marino F","year":"2020","unstructured":"Zito Marino F, Ronchi A, Stilo M, et al.. Multiplex HPV RNA in situ hybridization\/p16 immunohistochemistry: a novel approach to detect papillomavirus in HPV-related cancers. A novel multiplex ISH\/IHC assay to detect HPV. Infect Agent Cancer. 2020, 15:46. 10.1186\/s13027-020-00310-x","journal-title":"Infect Agent Cancer"},{"key":"ref5","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Cervical Cancer. Accessed. Accessed. July 1, 2024: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cervical.pdf."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctro.2018.01.001","article-title":"The EMBRACE II study: the outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies","volume":"9","author":"P\u00f6tter R","year":"2018","unstructured":"P\u00f6tter R, Tanderup K, Kirisits C, et al.. The EMBRACE II study: the outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies. Clin Transl Radiat Oncol. 2018, 9:48-60. 10.1016\/j.ctro.2018.01.001","journal-title":"Clin Transl Radiat Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.21873\/cdp.10008","article-title":"Stereotactic body radiation therapy boost in patients with cervical cancer ineligible for brachytherapy","volume":"1","author":"Facondo G","year":"2021","unstructured":"Facondo G, Vullo G, DE Sanctis V, et al.. Stereotactic body radiation therapy boost in patients with cervical cancer ineligible for brachytherapy. Cancer Diagn Progn. 2021, 1:53-60. 10.21873\/cdp.10008","journal-title":"Cancer Diagn Progn"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2008.10.006","article-title":"Treatment for patients with unknown primary cancer and favorable prognostic factors","volume":"36","author":"Hainsworth JD","year":"2009","unstructured":"Hainsworth JD, Fizazi K. Treatment for patients with unknown primary cancer and favorable prognostic factors. Semin Oncol. 2009, 36:44-51. 10.1053\/j.seminoncol.2008.10.006","journal-title":"Semin Oncol"},{"key":"ref9","unstructured":"Cancer stat facts. cervical cancer. (2024). Accessed: May 18, 2024: https:\/\/seer.cancer.gov\/statfacts\/html\/cervix.html."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15010060","article-title":"Anal cancer in high-risk women: the lost tribe","volume":"15","author":"Lupi M","year":"2022","unstructured":"Lupi M, Brogden D, Howell AM, Tekkis P, Mills S, Kontovounisios C. Anal cancer in high-risk women: the lost tribe. Cancers (Basel). 2022, 15:10.3390\/cancers15010060","journal-title":"Cancers (Basel)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26133874","article-title":"Selected in situ hybridization methods: principles and application","volume":"26","author":"Veselinyov\u00e1 D","year":"2021","unstructured":"Veselinyov\u00e1 D, Ma\u0161lankov\u00e1 J, Kalinov\u00e1 K, Mi\u010dkov\u00e1 H, Marekov\u00e1 M, Rabajdov\u00e1 M. Selected in situ hybridization methods: principles and application. Molecules. 2021, 26:10.3390\/molecules26133874","journal-title":"Molecules"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2010.0009","article-title":"Anal carcinoma therapy: can we improve on 5-fluorouracil\/mitomycin\/radiotherapy?","volume":"8","author":"Jiang Y","year":"2010","unstructured":"Jiang Y, Mackley H, Cheng H, Ajani JA. Anal carcinoma therapy: can we improve on 5-fluorouracil\/mitomycin\/radiotherapy?. J Natl Compr Canc Netw. 2010, 8:135-44. 10.6004\/jnccn.2010.0009","journal-title":"J Natl Compr Canc Netw"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2019-000735","article-title":"Intensity modulated radiation therapy boost in locally-advanced cervical cancer in the absence of brachytherapy","volume":"30","author":"Lazzari R","year":"2020","unstructured":"Lazzari R, Riva G, Augugliaro M, et al.. Intensity modulated radiation therapy boost in locally-advanced cervical cancer in the absence of brachytherapy. Int J Gynecol Cancer. 2020, 30:607-12. 10.1136\/ijgc-2019-000735","journal-title":"Int J Gynecol Cancer"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0000000000001155","article-title":"Tumor boost using external beam radiation in cervical cancer patients unable to receive intracavitary brachytherapy: outcome from a multicenter retrospective study (Korean Radiation Oncology Group 1419)","volume":"28","author":"Kim H","year":"2018","unstructured":"Kim H, Kim YS, Joo JH, et al.. Tumor boost using external beam radiation in cervical cancer patients unable to receive intracavitary brachytherapy: outcome from a multicenter retrospective study (Korean Radiation Oncology Group 1419). Int J Gynecol Cancer. 2018, 28:371-8. 10.1097\/IGC.0000000000001155","journal-title":"Int J Gynecol Cancer"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyz074","article-title":"Determining the recommended dose of stereotactic body radiotherapy boost in patients with cervical cancer who are unsuitable for intracavitary brachytherapy: a phase I dose-escalation study","volume":"49","author":"Ito K","year":"2019","unstructured":"Ito K, Kito S, Nakajima Y, et al.. Determining the recommended dose of stereotactic body radiotherapy boost in patients with cervical cancer who are unsuitable for intracavitary brachytherapy: a phase I dose-escalation study. Jpn J Clin Oncol. 2019, 49:856-61. 10.1093\/jjco\/hyz074","journal-title":"Jpn J Clin Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2019-001104","article-title":"Non-invasive stereotactic ablative boost in patients with locally advanced cervical cancer","volume":"30","author":"Dalwadi S","year":"2020","unstructured":"Dalwadi S, Echeverria A, Jhaveri P, et al.. Non-invasive stereotactic ablative boost in patients with locally advanced cervical cancer. Int J Gynecol Cancer. 2020, 30:1684-8. 10.1136\/ijgc-2019-001104","journal-title":"Int J Gynecol Cancer"},{"key":"ref17","unstructured":"ICRU report 89, prescribing, recording, and reporting brachytherapy for cancer of the cervix. (2025). Accessed. May 18, 2024: https:\/\/www.icru.org\/report\/icru-report-89-prescribing-recording-and-reporting-brachytherapy-for-cancer-of-the-cervix\/."},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0000000000001200","article-title":"Stereotactic body radiation therapy, intensity-modulated radiation therapy, and brachytherapy boost modalities in invasive cervical cancer. A study of the National Cancer Data Base","volume":"28","author":"O\u02bcDonnell B","year":"2018","unstructured":"O\u02bcDonnell B, Shiao JC, Pezzi TA, Waheed N, Sharma S, Bonnen MD, Ludwig MS. Stereotactic body radiation therapy, intensity-modulated radiation therapy, and brachytherapy boost modalities in invasive cervical cancer. A study of the National Cancer Data Base. Int J Gynecol Cancer. 2018, 28:563-74. 10.1097\/IGC.0000000000001200","journal-title":"Int J Gynecol Cancer"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1186\/s12911-016-0377-1","article-title":"Cognitive biases associated with medical decisions: a systematic review","volume":"16","author":"Saposnik G","year":"2016","unstructured":"Saposnik G, Redelmeier D, Ruff CC, Tobler PN. Cognitive biases associated with medical decisions: a systematic review. BMC Med Inform Decis Mak. 2016, 16:138. 10.1186\/s12911-016-0377-1","journal-title":"BMC Med Inform Decis Mak"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1136\/bmjqs-2011-000149","article-title":"Cognitive interventions to reduce diagnostic error: a narrative review","volume":"21","author":"Graber ML","year":"2012","unstructured":"Graber ML, Kissam S, Payne VL, et al.. Cognitive interventions to reduce diagnostic error: a narrative review. BMJ Qual Saf. 2012, 21:535-7. 10.1136\/bmjqs-2011-000149","journal-title":"BMJ Qual Saf"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/319792-a-curious-presentation-of-a-human-papillomavirus-hpv-driven-pelvic-squamous-cell-carcinoma-of-unknown-primary-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T21:15:21Z","timestamp":1744492521000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/319792-a-curious-presentation-of-a-human-papillomavirus-hpv-driven-pelvic-squamous-cell-carcinoma-of-unknown-primary-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,12]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.82134","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,12]]}}}